Bipolar Depression Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie Inc., GlaxoSmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H.

DelveInsight's "Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Bipolar Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bipolar Depression Market Forecast
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Bipolar Depression Market Report:
• The Bipolar Depression market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• Within the 7MM, the United States held the largest market size at approximately USD 2.3 billion in 2023, followed by Germany and Italy.
• In April 2024, NRx Pharmaceuticals reported encouraging results from their Phase IIb/III clinical trial comparing NRX-101 to lurasidone for treating suicidal bipolar depression. The trial showed a hopeful, though not statistically significant, 33% decrease in suicidality and a 70% reduction in akathisia symptoms (P=.076).
• According to DelveInsight's estimates, there were approximately 3.6 million prevalent cases of Bipolar Depression in the 7MM in 2023. Additionally, severe cases constituted the majority, making up about 75% of the total cases in that year.
• According to DelveInsight's estimates, in 2023, approximately 70% of the diagnosed prevalent cases of bipolar depression in the 7MM were in the United States.
• In the United States, severe cases made up the majority of cases based on severity, accounting for around 75% of the total in 2023.
• Key Bipolar Depression Companies: AbbVie Inc., Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
• Key Bipolar Depression Therapies: NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
• The number of cases of each type of bipolar depression in the US in 2021 was 934.9K for bipolar depression I and 1445.9K for bipolar depression II, respectively
• The Bipolar Depression market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bipolar Depression pipeline products will significantly revolutionize the Bipolar Depression market dynamics.

Bipolar Depression Overview
A mental illness known as bipolar disorder (BD) is characterized by mood swings between mania and depression. Bipolar disorder (BD) is primarily divided into BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS) based on the characteristics of the episodes.

Get a Free sample for the Bipolar Depression Market Report:
https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bipolar Depression Epidemiology Segmentation:
The Bipolar Depression market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Bipolar Depression
• Prevalent Cases of Bipolar Depression by severity
• Gender-specific Prevalence of Bipolar Depression
• Diagnosed Cases of Episodic and Chronic Bipolar Depression

Download the report to understand which factors are driving Bipolar Depression epidemiology trends @ Bipolar Depression Epidemiology Forecast
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bipolar Depression market or expected to get launched during the study period. The analysis covers Bipolar Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market :
The report also covers the Bipolar Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bipolar Depression Therapies and Key Companies
• NRX-100/ NRX-101: NeuroRx
• SEP-4199: Sunovion (Sumitomo Dainippon Pharma)
• COMP 360 (Psilocybin Therapy): COMPASS Pathways
• Sage-217: SAGE Therapeutics
• cariprazine: Forest Laboratories
• Ketamine Hydrochloride: Target Health Inc.
• Lurasidone HCl: Vanguard, Inc.
• Quetiapine Fumarate (SEROQUEL): AstraZeneca
• Esketamine: Celon Pharma SA
• Lumateperone: Intra-Cellular Therapies, Inc.
• Brexpiprazole: Otsuka America Pharmaceutical
• OSU6162: Arvid Carlsson Research AB
• Bifeprunox: Solvay Pharmaceuticals
• carbamazepine ER: Shire
• ITI-007 (Lumateperone): Intra-Cellular Therapies, Inc.
• Olanzapine Fluoxetine Combination (OFC): Eli Lilly and Company
• lamotrigine: GlaxoSmithKline
• FK949E: Astellas Pharma Inc
• SM-13496: Sumitomo Pharma Co., Ltd.

Discover more about therapies set to grab major Bipolar Depression market share @ Bipolar Depression Treatment Market
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Market Drivers
• Future Directions in Blood Biomarkers
• Increase in Awareness and Technology
• Advances Toward Precision Medicine for Bipolar Depression

Bipolar Depression Market Barriers
• Misdiagnosis of Bipolar Depression
• Unsatisfactory Design of RCTs
• Limited Understanding of the Disease Mechanism

Scope of the Bipolar Depression Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bipolar Depression Companies AbbVie Inc., GlaxoSmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
• Key Bipolar Depression Therapies: NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
• Bipolar Depression Therapeutic Assessment: Bipolar Depression current marketed and Bipolar Depression emerging therapies
• Bipolar Depression Market Dynamics: Bipolar Depression market drivers and Bipolar Depression market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bipolar Depression Unmet Needs, KOL's views, Analyst's views, Bipolar Depression Market Access and Reimbursement

To know more about Bipolar Depression companies working in the treatment market, visit @ Bipolar Depression Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Bipolar Depression Market Report Introduction
2. Executive Summary for Bipolar Depression
3. SWOT analysis of Bipolar Depression
4. Bipolar Depression Patient Share (%) Overview at a Glance
5. Bipolar Depression Market Overview at a Glance
6. Bipolar Depression Disease Background and Overview
7. Bipolar Depression Epidemiology and Patient Population
8. Country-Specific Patient Population of Bipolar Depression
9. Bipolar Depression Current Treatment and Medical Practices
10. Bipolar Depression Unmet Needs
11. Bipolar Depression Emerging Therapies
12. Bipolar Depression Market Outlook
13. Country-Wise Bipolar Depression Market Analysis (2020-2034)
14. Bipolar Depression Market Access and Reimbursement of Therapies
15. Bipolar Depression Market Drivers
16. Bipolar Depression Market Barriers
17. Bipolar Depression Appendix
18. Bipolar Depression Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports Offered By DelveInsight:

Charcot-marie-tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.

Dysfunctional Uterine Bleeding Market
https://www.delveinsight.com/report-store/dysfunctional-uterine-bleeding-market
DelveInsight's "Dysfunctional Uterine Bleeding Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dysfunctional Uterine Bleeding, historical and forecasted epidemiology as well as the Dysfunctional Uterine Bleeding market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Mrna Based Vaccines And Therapeutics Market
https://www.delveinsight.com/report-store/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market
DelveInsight's "Global Messenger RNA (mRNA)-based Vaccines and Therapeutics- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Global Messenger RNA (mRNA)-based Vaccines and Therapeutics, historical and forecasted epidemiology as well as the Global Messenger RNA (mRNA)-based Vaccines and Therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Papilloma Market
https://www.delveinsight.com/report-store/papilloma-market
DelveInsight's "Papilloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Papilloma, historical and forecasted epidemiology as well as the Papilloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Periodontal Disease Market
https://www.delveinsight.com/report-store/periodontal-disease-market
DelveInsight's "Periodontal Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Periodontal Disease, historical and forecasted epidemiology as well as the Periodontal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.